Quick Take
TFF Pharmaceuticals (TFFP) has filed to raise gross proceeds of $22 million from a U.S. IPO, according to an S-1 registration statement.
The firm is focused on developing and commercializing treatments for lung-related conditions.
TFFP is proposing a fairly low valuation at IPO but the firm is still at pre-Phase 1 trial stage, so the IPO is likely more relevant for long-term hold investors.
Company & Technology
Austin, Texas-based TFF was founded in 2018 to develop and commercialize drug products for the treatment of lung diseases and conditions based on